Below is a post and link from the PRR thread I thought would interest VHL holders regarding immunotherapies.
IMHO, it would be unwise to underestimate the huge positive effect this decision will surely have on all immunotherapy related companies in late stage development.
Could a VHL re-rating be imminent???
"One thing for sure is that IF/when Provenge gets approved that big pharma's would have to a t least start watching PRR's CVac progress alot closer and alot more often, otherwise they will be paying multiples if they wait too long.
If the below is any indication and all goes well for DNDN and PRR's own in-house developments, 2010 is bound to be a huge year for PRR....not to even mention 2011 and beyond"
A personalised tool to help users track selected stocks. Delivering real-time notifications on price updates, announcements, and performance stats on each to help make informed investment decisions.
(20min delay)